$SYRE News

Spyre Therapeutics (SYRE) Stock May Be Fully Priced Following New IBD Data Preview

BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026

UBS Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $120

Spyre Therapeutics (SYRE) Completed A $350 Million Public Stock Offering

Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential

Spyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below Market

Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock

Spyre Therapeutics stock falls on public offering launch

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

Spyre Therapeutics Announces Grants of Inducement Awards

JP Morgan Initiates Coverage On Spyre Therapeutics with Overweight Rating, Announces Price Target of $110

BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

What Does Spyre Therapeutics (SYRE) Part A Trial Success Mean For Ulcerative Colitis?

Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests

Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?

Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Wedbush Reiterates Outperform on Spyre Therapeutics, Maintains $123 Price Target

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations

BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target